捷顺科技：10月24日召开董事会会议

Group 1 - The core point of the article is that Jieshun Technology (SZ 002609) held its seventh second board meeting on October 24, 2025, to review the proposal for the company's Q3 2025 report [1] - For the first half of 2025, Jieshun Technology's revenue composition was 93.19% from security and 6.81% from other sources [1] - As of the report date, Jieshun Technology has a market capitalization of 6.3 billion yuan [1] Group 2 - The article also highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a hot secondary market in biomedicine [1] - There is a contrast noted between the thriving secondary market and the cooling fundraising environment in the primary market for biomedicine [1]